In addition, after n-3 PUFA supplementation, expression levels of transforming growth factor (TGF)-β, which is a marker of end-organ complications associated with DM, and those of interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1, markers of tissue inflammation, were attenuated [24]. This evidence concerns the gene CCL2 and diabetes mellitus.